Form 4: NextCure Executive Han Myint Acquires 93,900 Employee Stock Options
SEC Form 4 Filing
Han Myint, Chief Medical Officer of NextCure, Inc., acquired 93,900 employee stock options on March 29, 2024, according to a Form 4 filing with the SEC.
Summary
- According to a Form 4 filing with the SEC, Han Myint, the Chief Medical Officer of NextCure, Inc. acquired 93,900 employee stock options on March 29, 2024.
- The exercise price of each option is $2.23.
- The options vest in full on March 29, 2025, one year after the grant date, and expire on March 28, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions.
Stakeholder Impact
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/29/2024 | Date of transaction: Han Myint acquired 93,900 employee stock options. |
| 03/29/2025 | Date the options vest in full, one year after the grant date. |
| 03/28/2034 | Expiration date of the employee stock options. |
| 04/02/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.